亚太生物製剂药物研发市场：按製造商、类型和国家分類的分析和预测（2025-2035 年）

亚太地区生物製剂药物研发市场预计将从 2024 年的 48.7 亿美元成长到 2035 年的 167.1 亿美元，预测期（2025-2035 年）复合年增长率为 11.90%。

亚太地区的生物製剂研发市场正经历显着成长，这主要得益于慢性病和罕见疾病的日益增多以及精准医疗趋势的加速发展。单株抗体、重组蛋白和新一代疗法等生物製剂因其优于传统小分子药物的疗效和更高的特异性，在全部区域日益普及。中国、日本、韩国、印度和澳洲等国家不断扩大的产学合作、政府主导的研发计划以及不断完善的法规结构，都为该地区的生物製剂发展做出了贡献。

由于技术进步，亚太地区的药物研发格局正在迅速改变。人工智慧驱动的标靶发现、高通量筛检、多体学平台和先进抗体设计工具的整合，正在增强该地区的创新能力并提高早期研发效率。然而，研究基础设施的异质性、监管成熟度的差异、高昂的研发成本以及部分国家有限的生物製药生产能力等障碍，仍限制研发进程。但不断增长的投资、对区域性合约研究组织（CRO）和合约研发生产机构（CDMO）日益增长的外包需求，以及对个性化和基于机制治疗方法的快速增长的需求，正使该地区成为生物製药研发和未来治疗创新领域快速发展的中心。

市场概览

罕见疾病和慢性病的日益增多、对个人化治疗需求的成长以及亚太地区医疗基础设施的不断完善，共同推动了该地区生物製剂药物研发市场的显着成长。在政府资助的研究计划、产学合作以及不断壮大的专业合约研究组织（CRO）和合约研发生产组织（CDMO）网路的推动下，中国、日本、韩国、印度和澳洲等国家正成为生物製剂研发的重要中心。与传统小分子药物相比，生物製剂，包括单株抗体、重组蛋白、多特异性抗体和基因疗法等新一代疗法，因其更高的特异性、有效性和安全性而日益受到青睐。

技术创新正在加速该地区的药物研发进程。先进的抗体工程、多体学整合、高通量筛检以及人工智慧驱动的目标发现技术正在提高早期研究的效率和成功率。此外，数位技术和真实世界数据的应用正在推动生物标记主导的药物研发和精准医疗策略的发展。

儘管取得了这些进展，但仍存在许多障碍，包括研发成本不断上涨、生产流程复杂以及监管成熟度和合格人才供应方面的区域差异。然而，外包模式的扩展、公共和私营部门投资的增加以及对个人化医疗日益增长的关注，已使亚太地区成为生物製剂药物研发的快速发展中心，并有望在未来十年为全球治疗创新做出重大贡献。

市场区隔:

细分 1：依生产类型

• 内部生产
• 外包委託製造

细分 2：按类型

• 单株抗体
• 重组蛋白
• 其他生物製剂

细分3：按地区

• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 其他的

本报告检视了亚太地区的生物製剂药物研发市场，并总结了关键趋势、市场影响因素分析、法律制度、市场规模趋势和预测、按各个细分市场、地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章：生物製剂药物研发市场：产业展望

• 市场概览
• 主要市场趋势
  • 双特异性和多特异性抗体研发进展
  • 加强伙伴关係与合作
  • 对外包服务的需求不断增长
• 监管状态
  • 亚太地区
• 供应链分析
  • 供应炼及其风险
• 专利分析
  • 专利申请趋势（按国家/地区划分）
  • 专利申请趋势（按年份）
• 市场动态
  • 市场驱动因素
  • 市场挑战
  • 市场机会

第二章：生物製剂药物研发市场（依地区分）

• 亚太地区
  • 区域概览
  • 市场成长驱动因素
  • 市场问题
  • 市场规模及预测

第三章 竞争基准化分析与公司概况

• 公司简介
  • Astellas Pharma Inc.
  • GenScript Biotech Corporation
  • WuXi Biologics (Cayman) Inc.

第四章调查方法

This report can be delivered in 2 working days.

Introduction to Asia-Pacific Biologics Drug Discovery Market

The Asia-Pacific biologics drug discovery market is projected to reach $16.71 billion by 2035 from $4.87 billion in 2024, growing at a CAGR of 11.90% during the forecast period 2025-2035. As the region deals with an increasing number of chronic and rare diseases as well as an accelerating trend toward precision-focused medicines, the APAC biologics drug development market is gaining significant traction. Because they provide better therapeutic outcomes and greater specificity than conventional small drugs, biologics-such as monoclonal antibodies, recombinant proteins, and next-generation modalities-are becoming more and more popular throughout APAC. Growing academic-industry collaborations, government-led R&D projects, and changing regulatory frameworks in nations like China, Japan, South Korea, India, and Australia all contribute to the region's advancement.

APAC's discovery landscape is rapidly changing due to technological improvements. The region's ability for innovation is being strengthened and early-stage efficiency is being improved through the integration of AI-driven target identification, high-throughput screening, multi-omics platforms, and sophisticated antibody-engineering tools. Despite this expansion, obstacles like uneven research infrastructure, inconsistent regulatory maturity, high development costs, and restricted biologics manufacturing capacity in some countries continue to influence the rate of advancement. Nevertheless, APAC is becoming a rapidly developing center for biologics drug development and future therapeutic innovation due to growing investments, increasing outsourcing to regional CROs and CDMOs, and accelerated demand for individualized and mechanism-based treatments.

Market Introduction

The growing prevalence of uncommon and chronic diseases, the growing need for tailored treatments, and the development of the region's healthcare infrastructure are all contributing factors to the APAC biologics drug discovery market's notable expansion. With the help of government-funded research projects, industry-academia partnerships, and an expanding network of specialized CROs and CDMOs, nations like China, Japan, South Korea, India, and Australia are becoming important centers for biologics R&D. Because they are more specific, effective, and safe than traditional small drugs, biologics-which include monoclonal antibodies, recombinant proteins, and next-generation modalities like multispecific antibodies and gene therapies-are becoming more and more popular.

The region's discovery pipelines are being accelerated by technological advancements. Advanced antibody engineering, multi-omics integration, high-throughput screening, and AI-driven target discovery are increasing the effectiveness and success rates of early-stage research. Furthermore, the use of digital technologies and real-world data is improving biomarker-driven drug development and precision medicine strategies.

Notwithstanding these developments, there are still many obstacles to overcome, including expensive research costs, intricate manufacturing specifications, and differences in regulatory maturity and qualified personnel within APAC markets. However, growing outsourcing models, rising public and private sector investment, and an increasing emphasis on personalized medicine are positioning APAC as a rapidly developing hub for biologics drug discovery, with the potential to make a substantial contribution to global therapeutic innovation over the next ten years.

Market Segmentation:

Segmentation 1: By Manufacturing Type

• In-House Manufacturing
• Outsourced Manufacturing

Segmentation 2: By Type

• Monoclonal Antibodies
• Recombinant Proteins
• Other Biologics

Segmentation 3: By Region

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

APAC Biologics Drug Discovery Market Trends, Drivers and Challenges

Market Trends

• Strong adoption of monoclonal antibodies, recombinant proteins, and next-generation biologics such as gene and cell therapies.
• Increasing use of AI, machine learning, and computational tools for target identification and lead optimization.
• Expansion of public-private partnerships and collaborations between pharma, biotech, and academic institutions.
• Growing outsourcing to regional CROs and CDMOs for specialized biologics R&D and manufacturing.
• Rising focus on precision medicine and biomarker-driven approaches across therapeutic areas like oncology, immunology, and neurology.

Market Growth Drivers

• Rising prevalence of chronic, autoimmune, and rare diseases across APAC, fueling demand for innovative biologics.
• Government-backed R&D funding and supportive regulatory frameworks enhancing research capabilities.
• Technological advancements, including high-throughput screening, multi-omics analysis, and antibody engineering.
• Increasing investments from pharma, biotech, and venture capital supporting early-stage discovery.
• Adoption of digital tools and real-world evidence to optimize drug development and clinical success rates.

Market Challenges

• High development and manufacturing costs for biologics, particularly for advanced modalities.
• Regulatory variability across APAC countries creating delays and complexity in approvals.
• Limited skilled talent in biologics discovery, CMC, and regulatory sciences in certain markets.
• Infrastructure disparities, including availability of specialized labs and biologics manufacturing facilities.
• Supply-chain vulnerabilities for APIs and reliance on regional CDMOs, leading to potential delays and cost pressures.

How can this report add value to an organization?

Product/Innovation Strategy: The APAC biologics drug discovery market has been extensively segmented based on various categories, such as manufacturing type, type, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and business expansions have accounted for the majority of key developments.

Competitive Strategy: The APAC biologics drug discovery market has numerous established players with product portfolios. Key players in the APAC biologics drug discovery market, analyzed and profiled in the study, include established players offering platforms, products, and services for biologics drug discovery.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Astellas Pharma Inc.
• GenScript Biotech Corporation
• WuXi Biologics (Cayman) Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Biologics Drug Discovery Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Key Market Trends
  • 1.2.1 Growth of Bispecific and Multispecific Antibody Development
  • 1.2.2 Rising Partnerships and Collaborations
  • 1.2.3 Rising Demand for Outsourcing Services
• 1.3 Regulatory Landscape
  • 1.3.1 Asia-Pacific
    • 1.3.1.1 China
    • 1.3.1.2 Japan
• 1.4 Supply Chain Analysis
  • 1.4.1 Supply Chain and Risks within the Supply Chain
• 1.5 Patent Analysis
  • 1.5.1 Patent Filing Trend (by Country)
  • 1.5.2 Patent Filing Trend (by Year)
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics in Treatment
    • 1.6.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
  • 1.6.2 Market Challenges
    • 1.6.2.1 High Development and Manufacturing Costs Hindering the Growth of the Market
  • 1.6.3 Market Opportunities
    • 1.6.3.1 AI Integration in Biologics Discovery

2 Biologics Drug Discovery Market (by Region), ($Billion), 2023-2035

• 2.1 Asia-Pacific
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Market Sizing and Forecast
    • 2.1.4.1 Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
    • 2.1.4.2 Asia-Pacific Biologics Drug Discovery Market, by Type
    • 2.1.4.3 Asia-Pacific Biologics Drug Discovery Market, by Country
      • 2.1.4.3.1 China
        • 2.1.4.3.1.1 Country Overview
        • 2.1.4.3.1.2 Driving Factors for Market Growth
        • 2.1.4.3.1.3 Factors Challenging the Market
        • 2.1.4.3.1.4 Market Sizing and Forecast
        • 2.1.4.3.1.4.1 China Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.1.4.2 China Biologics Drug Discovery Market, by Type
      • 2.1.4.3.2 Japan
        • 2.1.4.3.2.1 Country Overview
        • 2.1.4.3.2.2 Driving Factors for Market Growth
        • 2.1.4.3.2.3 Factors Challenging the Market
        • 2.1.4.3.2.4 Market Sizing and Forecast
        • 2.1.4.3.2.4.1 Japan Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.2.4.2 Japan Biologics Drug Discovery Market, by Type
      • 2.1.4.3.3 India
        • 2.1.4.3.3.1 Country Overview
        • 2.1.4.3.3.2 Driving Factors for Market Growth
        • 2.1.4.3.3.3 Factors Challenging the Market
        • 2.1.4.3.3.4 Market Sizing and Forecast
        • 2.1.4.3.3.4.1 India Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.3.4.2 India Biologics Drug Discovery Market, by Type
      • 2.1.4.3.4 South Korea
        • 2.1.4.3.4.1 Country Overview
        • 2.1.4.3.4.2 Driving Factors for Market Growth
        • 2.1.4.3.4.3 Factors Challenging the Market
        • 2.1.4.3.4.4 Market Sizing and Forecast
        • 2.1.4.3.4.4.1 South Korea Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.4.4.2 South Korea Biologics Drug Discovery Market, by Type
      • 2.1.4.3.5 Australia
        • 2.1.4.3.5.1 Country Overview
        • 2.1.4.3.5.2 Driving Factors for Market Growth
        • 2.1.4.3.5.3 Factors Challenging the Market
        • 2.1.4.3.5.4 Market Sizing and Forecast
        • 2.1.4.3.5.4.1 Australia Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.5.4.2 Australia Biologics Drug Discovery Market, by Type
      • 2.1.4.3.6 Rest-of-Asia-Pacific
        • 2.1.4.3.6.1 Country Overview
        • 2.1.4.3.6.2 Driving Factors for Market Growth
        • 2.1.4.3.6.3 Factors Challenging the Market
        • 2.1.4.3.6.4 Market Sizing and Forecast
        • 2.1.4.3.6.4.1 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.6.4.2 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Type

3 Competitive Benchmarking and Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Astellas Pharma Inc.
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products/Product Portfolio
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Target Customers
    • 3.1.1.5 Key Personal
    • 3.1.1.6 Analyst View
  • 3.1.2 GenScript Biotech Corporation
    • 3.1.2.1 Overview
    • 3.1.2.2 Top Products/Product Portfolio
    • 3.1.2.3 Top Competitors
    • 3.1.2.4 Target Customers
    • 3.1.2.5 Key Personal
    • 3.1.2.6 Analyst View
  • 3.1.3 WuXi Biologics (Cayman) Inc.
    • 3.1.3.1 Overview
    • 3.1.3.2 Top Products/Product Portfolio
    • 3.1.3.3 Top Competitors
    • 3.1.3.4 Target Customers
    • 3.1.3.5 Key Personal
    • 3.1.3.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figure

• Figure 1: Asia-Pacific Biologics Drug Discovery Market (by Scenario), $Billion, 2024, 2029, and 2035
• Figure 2: Asia-Pacific Biologics Drug Discovery Market, 2024 and 2035
• Figure 3: Biologics Drug Discovery Market, $Billion, 2025 and 2035
• Figure 4: Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
• Figure 5: Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
• Figure 6: Number of Patents Filed (by Country), January 2021 to 12th September 2025
• Figure 7: Number of Patents Filed (by Year), January 2021 to 12th September 2025
• Figure 8: Incidence of Cancer (by Region), 2020-2040
• Figure 9: Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 10: China Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 11: Japan Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 12: India Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 13: South Korea Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 14: Australia Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 15: Rest-of-Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 16: Data Triangulation
• Figure 17: Top-Down and Bottom-Up Approach
• Figure 18: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Biologics Drug Discovery Market, Key Market Trends
• Table 3: Key Partnerships in the Biologics Drug Discovery Market
• Table 4: Market Dynamics
• Table 5: Biologics Drug Discovery Market (by Region), $Billion, 2023-2035
• Table 6: Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 7: Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 8: Asia-Pacific Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
• Table 9: China Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 10: China Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 11: Japan Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 12: Japan Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 13: India Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 14: India Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 15: South Korea Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 16: South Korea Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 17: Australia Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 18: Australia Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 19: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 20: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035